Outpatient management of chronic heart failure

Bibliography

• Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail 2008;10(10):933-89
   PubMed Web of Science ®Google Scholar
• Frigola-Capell E, Comin-Colet J, Davins-Miralles J, et al. Survival in Mediterranean ambulatory patients with chronic heart failure. A population-based study. Rev Esp Cardiol 2013;66(7):539-44
   Google Scholar
• Mcmurray JJ, Stewart S. Heart failure epidemiology, aetiology, and prognosis of heart failure. Heart 2000;83:596-602
   PubMed Web of Science ®Google Scholar
• Ho KKL, Anderson KM, Karmel WB, et al. Survival after the onset of congestive heart failure in the Framingham heart study subjects. Circulation 1993;88:107-15
   PubMed Web of Science ®Google Scholar
• Skeggs LT, Dorer FE, Kahn JR, et al. The biochemistry of the renin–angiotensin system and its role in hypertension. Am J Med 1976;60:737-48
   PubMed Web of Science ®Google Scholar
• Spinarova L, Vitovec J. Neurohumoral changes in chronic heart failure. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007;151(2):201-7
   Google Scholar
• Ma TK, Kam KK, Yan BP, Lam YY. Renin–angiotensin–aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010;160(6):1273-92
   PubMed Web of Science ®Google Scholar
• Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD investigators Am Coll Cardiol 1994;23:1410-20
   PubMed Web of Science ®Google Scholar
• Mcmurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-69
   PubMed Web of Science ®Google Scholar
• Raman VK, Lee YA, Lindpaintner K. The cardiac renin–angiotensin–aldosterone system and hypertensive cardiac hypertrophy. Am J Cardiol 1995;76:18D-23D
   Google Scholar
• Dostal DE, Baker KM. The cardiac renin–angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999;85:643-50
   PubMed Web of Science ®Google Scholar
• Otani H, Otsuka F, Inagaki K, et al. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology 2008;149(6):2816-25
   Google Scholar
• Schunkert H, Ingelfinger JR, Hirsch AT, et al. Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. J Clin Invest 1992;90:1523-9
   Google Scholar
• Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000;32:865-79
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Izumo S. Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. CircRes 1993;73:413-23
   Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 1992;327:685-91
   PubMed Web of Science ®Google Scholar
• Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843-8
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVEInvestigators. N Engl J Med 1992;327(10):669-77
   PubMed Web of Science ®Google Scholar
• Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333(25):1670-6
   PubMed Web of Science ®Google Scholar
• Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. The NETWORK Investigators. Eur Heart J 1998;19:481-9
   PubMed Web of Science ®Google Scholar
• Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure: the role of angiotensin-converting enzyme inhibitors. Arch Intern Med 1998;158:2024-8
   PubMedGoogle Scholar
• Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a metaanalysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38
   PubMed Web of Science ®Google Scholar
• Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 2003;138:917-24
   PubMed Web of Science ®Google Scholar
• Pedrino GR, Rosa DA, Lopes OU, Cravo SL. Neurobiology of body fluid homeostasis: transduction and integration. Chapter 8. De Luca LA Jr, Menani JV, Johnson AK, editors. Catecholaminergic medullary pathways and cardiovascular responses to expanded circulating volume and increased osmolarity; Boca Raton, FL: CRC Press; 2014
   Google Scholar
• Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001;104:1985-91
   PubMed Web of Science ®Google Scholar
• Sánchez-Borges M, González-Aveledo LA. Angiotensin-converting enzyme inhibitors and angioedema. Allergy Asthma Immunol Res 2010;2(3):195-8
   PubMed Web of Science ®Google Scholar
• Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010;40:50-61
   PubMed Web of Science ®Google Scholar
• Andrew N, Gabb G, Del Fante M. ACEI associated angioedema - a case study and review. Aust Fam Physician 2011;40(12):985-8
   Google Scholar
• Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV, ACE inhibition, and angioedema. Hypertension 2008;51:141-7
   PubMed Web of Science ®Google Scholar
• Duan QL, Nikpoor B, Dube M, et al. A variant in XPNPEP2 is associated with angioedema induced by angiotensin -converting enzyme inhibitors. Am J Hum Genet 2005;77:617-26
   PubMed Web of Science ®Google Scholar
• Hedner T, Samuelsson O, Lunde H, et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BM J 1992;304:941
   PubMed Web of Science ®Google Scholar
• Jones RL, Gabb GM. Angioedema and ACE inhibitors or angiotensin II receptor blockers, revisited. Pharmacoepidemiol Drug Saf 2010;19:S145
   Google Scholar
• Grant NN, Deeb ZE, Chia SH. Clinical experience with angiotensin-converting enzyme inhibitorinduced angioedema. Otolaryngol Head Neck Surg 2007;137:931-5
   Google Scholar
• Weir MR, Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010;5:531-48
   PubMed Web of Science ®Google Scholar
• Guichard JL, Clark DIII, Calhoun DA, Ahmed MI. Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag 2013;9:321-31
   PubMedGoogle Scholar
• Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-7
   PubMed Web of Science ®Google Scholar
• Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345(23):1689-97
   PubMed Web of Science ®Google Scholar
• Pitt B. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995;9(1):145-9
   PubMed Web of Science ®Google Scholar
• Jorde UP, Vittorio T, Katz SD, et al. Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure. Circulation 2002;106(9):1055-7
   Google Scholar
• Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10):709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348(14):1309-21
   PubMed Web of Science ®Google Scholar
• Zannad F, Mcmurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364(1):11-21
   PubMed Web of Science ®Google Scholar
• Zannad F, Gattis Stough W, Rossignol P, et al. Mineralocorticoid receptor antagonists for heartfailure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33:2782-95
   PubMed Web of Science ®Google Scholar
• Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blockingagents eplerenone and spironolactone. Clin Cardiol 2008;31:153-8
   PubMed Web of Science ®Google Scholar
• Guglin M, Kristof-Kuteyeva O, Novotorova I, Pratap P. Aldosterone antagonistsin heart failure. J Cardiovasc Pharmacol Ther 2011;16:150-9
   Google Scholar
• Yamaji M, Tsutamoto T, Kawahara C, et al. Effect of eplerenone versus spironolactone on cortisol and hemoglobinA(c) levels in patients with chronic heart failure. Am Heart J 2010;160:915-21
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Abuissa H, Pitt B. Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS. Diabetes Obes Metab 2008;10:492-7
   PubMed Web of Science ®Google Scholar
• Maron BA, Leopold JA. Aldosterone receptor antagonists: effective but often forgotten. Circulation 2010;121:934-9
   PubMed Web of Science ®Google Scholar
• Pitt B, Bakris G, Ruilope LM, EPHESUS Investigators. Serum potassium and Clinical Outcomes in the Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008;118:1643-50
   PubMedGoogle Scholar
• Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). Am Coll Cardiol 2012;60(20):2082-9
   PubMed Web of Science ®Google Scholar
• Rossignol P, Dobre D, McMurray JJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7(1):51-8
   PubMed Web of Science ®Google Scholar
• Granneman JG. The putative beta4-adrenergic receptor is a novel state of the beta1-adrenergic receptor. Am J Physiol Endocrinol Metab 2001;280(2):E199-202
   Google Scholar
• Macdonald PS, Keogh AM, Aboyoun CL, et al. Tolerability and efficacy of carvedilol in patients withNew York Heart Association class IV heart failure. J Am Coll Cardiol 1999;33:924-31
   PubMed Web of Science ®Google Scholar
• Rengo G, Lymperopoulos A, Leosco D, Koch WJ. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 2011;50(5):785-92
   Google Scholar
• Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ. Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. Circulation 1998;98(17):1783-9
   PubMed Web of Science ®Google Scholar
• Rengo G, Perrone-Filardi P, Femminella GD, et al. Targeting the beta-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ Heart Fail 2012;5(3):385-91
   Google Scholar
• Dedkov EI, Christensen LP, Weiss RM, Tomanek RJ. Reduction of heart rate by chronic beta1-adrenoceptor blockade promotes growth of arterioles and preserves coronary perfusion reserve in postinfarcted heart. Am J Physiol Heart Circ Physiol 2005;288(6):H2684-93
   Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8
   PubMed Web of Science ®Google Scholar
• Klapholz M. beta-blocker use for the stages of heart failure. Mayo Clin Proc 2009;84(8):718-29
   PubMed Web of Science ®Google Scholar
• Wikstrand J, Wedel H, Castagno D, McMurray JJ. The large-scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS-II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. Intern Med 2014;275(2):134-43
   Google Scholar
• Dobre D, van Veldhuisen DJ, Mordenti G, et al. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154(1):109-15
   Google Scholar
• Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013;346:f55
   PubMedGoogle Scholar
• Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38
   PubMed Web of Science ®Google Scholar
• Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004;43:1423-9
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, D’aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002;40:1248-58
   PubMed Web of Science ®Google Scholar
• Remme WJ, Riegger G, Hildebrandt P, et al. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57-66
   PubMed Web of Science ®Google Scholar
• Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004;44:1825-30
   PubMed Web of Science ®Google Scholar
• Routier G. Acute pulmonary edema in carbon monoxide poisoning. Value of intravenous acetazolamide. J Sci Med Lille 1962;80:352-4
   Google Scholar
• Ledingham JG. Ethacrynic acid parenterally in the treatment and prevention of pulmonary edema. Lancet 1964;1:952-4
   Google Scholar
• Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 2006;113:1020-7
   PubMed Web of Science ®Google Scholar
• Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95:2660-7
   PubMed Web of Science ®Google Scholar
• Damman K, Voors AA, Hillege HL, et al. CIBIS-2 Investigators and Committees. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010;12:974-82
   Google Scholar
• Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96
   PubMed Web of Science ®Google Scholar
• Damman K, Ng Kam Chuen MJ, MacFadyen RJ, et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J Am Coll Cardiol 2011;57:2233-41
   PubMed Web of Science ®Google Scholar
• Gaillourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clin Liver Dis 2002;6:947-67
   Google Scholar
• Meyers RP, Cerini R, Sayegh R, et al. Cardiac hepatopathy: clinical, hemodynamic and histologic characteristics and correlations. Hepatology 2003;37:393-400
   Google Scholar
• Westenbrink BD, Visser FW, Voors AA, et al. Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166-71
   PubMed Web of Science ®Google Scholar
• Gupta S, Neyses L. Diuretic usage in heart failure: a continuing conundrum in 2005. Eur Heart J 2005;26(7):644-9
   PubMed Web of Science ®Google Scholar
• Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011;13(9):639-43
   PubMed Web of Science ®Google Scholar
• Michael Felker G. Diuretic management in heart failure. Congest Heart Fail 2010;16(Suppl 1):S68-72
   Google Scholar
• Felker GM, Mentz RJ. Diuretics and ultrafiltration in acute decompensated heart failure. J Am Coll Cardiol 2011;59:24
   Google Scholar
• Wargo KA, Banta WM. A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother 2009;43(11):1836-47
   PubMed Web of Science ®Google Scholar
• Dinicolantonio JJ. Should torsemide be the loop diuretic of choice in systolic heart failure? Future Cardiol 2012;8(5):707-28
   PubMedGoogle Scholar
• Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-15
   PubMed Web of Science ®Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart-failure - activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6
   PubMed Web of Science ®Google Scholar
• Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22
   PubMedGoogle Scholar
• Tomaschitz A, Pilz S, Ritz E, et al. Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. Eur Heart J 2011;32:2642-9
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-62
   PubMed Web of Science ®Google Scholar
• Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8
   PubMed Web of Science ®Google Scholar
• Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96:132-43
   PubMed Web of Science ®Google Scholar
• Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010;36:19
   Google Scholar
• Oster JR, Epstein M, Smoller S. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med 1983;99:405-6
   PubMed Web of Science ®Google Scholar
• Selby VN, Teerlink JR. What’s new in the treatment of acute heart failure? Curr Cardiol Rep 2013;15:393
   Google Scholar
• Branch RA, Roberts CJ, Homeida M, Levine D. Determinants of response to frusemide in normal subjects. Br J Clin Pharmacol 1977;4(2):121-7
   Google Scholar
• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364(9):797-805
   PubMed Web of Science ®Google Scholar
• Shah RV, Mcnulty S, O’connor CM, et al. Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. Am Heart J 2012;164(6):862-8
   Google Scholar
• Copeland JG, Campbell DW, Plachetka JR, et al. Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 1983;146(6):796-9
   Google Scholar
• van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of furosemide pharmacokinetics. Biopharm Drug Dispos 2014;35:119-33
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 2013;128:e240-327
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8
   PubMed Web of Science ®Google Scholar
• Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759-64
   PubMed Web of Science ®Google Scholar
• Abdel-Qadir HM, Tu JV, Yun L, et al. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 2010;160:264-71
   PubMed Web of Science ®Google Scholar
• Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008;14:388-93
   PubMed Web of Science ®Google Scholar
• Agrawal V, Agrawal M, Joshi SR, Ghosh AK. Hyponatremia and hypernatremia: disorders of water balance. J Assoc Physicians India 2008;50:956-64
   Google Scholar
• Singer GG, Brenner BM. Fluid and electrolyte disturbances. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 16th edition. Volume 1 Mc Graw Hill; New York: 2005. p. 252-62
   Google Scholar
• Grinstead WC, Francis MJ, Marks GF, et al. Discontinuation of chronic diuretic therapy in stable congestiveheart failure secondary to coronary artery disease or to idiopathic dilatedcardiomyopathy. Am J Cardiol 1994;73:881-6
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009;374(9704):1840-8
   PubMed Web of Science ®Google Scholar
• Konstam MA, Neaton JD, Poole-Wilson PA, et al. Comparison of losartan and captopril on heart failurerelatedoutcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 2005;150:123-31
   PubMed Web of Science ®Google Scholar
• Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000;2(3):258-62
   PubMedGoogle Scholar
• Balcells E, Meng QC, Johnson WH J, et al. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273:1769-74
   PubMed Web of Science ®Google Scholar
• Phillips CO, Kashani A, Ko DK, et al. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167(18):1930-6. Review
   PubMedGoogle Scholar
• Mann JF, Schmieder RE, Mcqueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGETstudy): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-53
   PubMed Web of Science ®Google Scholar
• Manning M, Stoev S, Chini B, et al. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res 2008;170:473-512
   PubMed Web of Science ®Google Scholar
• Decaux G, Soupart A, Vassart G. Non-peptide arginine vasopressin antagonists: the vaptans. Lancet 2008;371:1624-32
   PubMed Web of Science ®Google Scholar
• Aditya S, Rattan A. Vaptans: a new option in the management of hyponatremia. J Appl Basic Med Res 2012;2(2):77-83
   PubMedGoogle Scholar
• Gheorghiade M, Konstam MA, Burnett JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297(12):1332-43
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. JAMA 2007;297(12):1319-31
   PubMedGoogle Scholar
• Ali F, Guglin M, Vaitkevicius P, Ghali JK. Therapeutic potential of vasopressin receptor antagonists. Drugs 2007;67(6):847-58; Review
   PubMed Web of Science ®Google Scholar
• Hauptman PJ, Burnett J, Gheorghiade M, et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013;19:390-7
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Hyponatremia in patients with heart failure. World J Cardiol 2013;5(9):317-28
   PubMedGoogle Scholar
• Ferrari R. Ivabradine: heart rate and left ventricular function. Cardiology 2014;128(2):226-30
   Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet 2010;376(9744):875-85
   PubMed Web of Science ®Google Scholar
• Borer JS, Böhm M, Ford I, et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014;113(3):497-503
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Böhm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitorivabradine Trial) study. J Am Coll Cardiol 2012;59(22):1938-45
   Google Scholar
• Corbalán R, Kunstmann S, Jalil J. Vasodilator agents in chronic heart failure: which is the best option? Rev Med Chil 1993;121(1):81-8
   Google Scholar
• Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986;314(24):1547-52
   PubMed Web of Science ®Google Scholar
• TAylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57
   PubMed Web of Science ®Google Scholar
• Ghali JK, Tam SW, Ferdinand KC, et al. Effects of ACE inhibitors or beta-blockers in patients treated with the fixed-dose combination of isosorbide dinitrate/hydralazine in the African-American Heart Failure Trial. Am J Cardiovasc Drugs 2007;7(5):373-80
   Google Scholar
• CHENG JW. A review of isosorbide dinitrate and hydralazine in the management of heart failure in black patients, with a focus on a new fixed-dose combination. Clin Ther 2006;28(5):666-78
   Google Scholar
• Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American heart failure trial. Am J Cardiol 2014;114(1):151-9
   PubMed Web of Science ®Google Scholar
• Zarowitz BJ, Gheorghiade M. Optimal heart rate control for patients with chronic atrial fibrillation: are pharmacologic choices truly changing? Am Heart J 1992;123:1401-3
   Google Scholar
• Krum H, Bigger JT, Goldsmith RL, et al. Effect of long-term digoxin therapy onautonomic function in patients with chronic heart failure. J Am Coll Cardiol 1995;25:289-94
   PubMed Web of Science ®Google Scholar
• Ferguson DW, Berg WJ, Sanders JS, et al. Sympathoinhibitory responses to digitalisglycosides in heart failure patients: direct evidence from sympathetic neural recordings. Circulation 1989;80:65-77
   PubMed Web of Science ®Google Scholar
• Newton GE, Tong JH, Schofield AM, et al. Digoxin reduces cardiac sympathetic activity in severe congestive heart failure. J Am Coll Cardiol 1996;28:155-61
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Hall VB, Jacobsen G, et al. Effects of increasing maintenance dose ofdigoxin on left ventricular function and neurohormones in patients with chronic heart failure treated with diuretics and angiotensin- converting enzyme inhibitors. Circulation 1995;92(7):1801-7
   Google Scholar
• Gheorghiade M, Adams KF, et al. Digoxin in the management of cardiovascular disorders. Circulation 2004;109:2959-64
   PubMed Web of Science ®Google Scholar
• The effect ofdigoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33
   PubMed Web of Science ®Google Scholar
• Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11
   PubMed Web of Science ®Google Scholar
• Ather S, Peterson LE, Divakaran VG, et al. Digoxin treatment in heart failure–unveiling risk by cluster analysis of DIG data. Int J Cardiol 2011;150(3):264-9
   Google Scholar
• Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Patel K, Filippatos G, et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail 2013;15:551-9
   Web of Science ®Google Scholar
• Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post-hoc analysis of the DIG trial. Eur Heart J 2006;27(2):178-86
   PubMed Web of Science ®Google Scholar
• Dotsenko O, Kakkar VV. Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications. J Thromb Haemost 2007;5(2):224-31
   Google Scholar
• Cleland JG, Findlay I, Jafri S, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148(1):157-64
   PubMed Web of Science ®Google Scholar
• Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur J Heart Fail 2006;8(4):42832
   Google Scholar
• Lip Gy, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2014;3:CD003336 doi:10.1002/14651858
   Google Scholar
• Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. EurHeartJ 1996;17(9):1390-403
   Google Scholar
• Hallstrom A, Pratt CM, Greene HL, et al. Relations between heart failure, ejection fraction, arrhythmia suppression and mortality: analysis of the Cardiac Arrhythmia Suppression Trial. J Am Coll Cardiol 1995;25(6):1250-7
   Google Scholar
• Waldo AL, Camm AJ, Deruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348(9019):7-12
   PubMed Web of Science ®Google Scholar
• Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333(2):77-82
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. A miodarone or an implantable cardioverter-defibrillator for congestive heart failure. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. N Engl J Med 2005;352(3):225-37. Erratum in N Engl J Med 2005;352(20):2146
   PubMed Web of Science ®Google Scholar
• Roy D, Talajic M, Dorian P, Connolly S. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342(13):913-20
   PubMed Web of Science ®Google Scholar
• Goldschlager N, Epstein AE, Naccarelli GV, et al. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4(9):1250-9
   PubMed Web of Science ®Google Scholar
• Elkayam U, Amin J, Mehra A, et al. A prospective, randomized, double-blind, crossover study to compare the efficacy and safety of chronic nifedipine therapy with that of isosorbide dinitrate and their combination in the treatment of chronic congestive heart failure. Circulation 1990;82:1954-61
   PubMed Web of Science ®Google Scholar
• Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failurein postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60
   PubMed Web of Science ®Google Scholar
• Effect ofverapamil on mortality and major events after acute myocardial infarction (theDanish Verapamil Infarction Trial IIDAVIT II). Am J Cardiol 1990;66:779-85
   PubMed Web of Science ®Google Scholar
• Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronicheart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107-14
   PubMed Web of Science ®Google Scholar
• Thackray S, Witte K, Clark AL, Cleland JG. Clinical trials update: optime-CHF, Praise-2, All-Hat. Eur J Heart Fail 2000;2:209-12
   PubMed Web of Science ®Google Scholar
• Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy inpatients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96:856-63
   PubMed Web of Science ®Google Scholar
• Motte S, Mcentee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006;110:386
   PubMed Web of Science ®Google Scholar
• Tostes RCA, Muscara MN. Endothelin receptor antagonists: another potential alternative for cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:287
   PubMedGoogle Scholar
• Ertl G, Bauersachs J. Endothelin receptor antagonists in heart failure: current status and future directions. Drugs 2004;64(10):1029-40
   PubMed Web of Science ®Google Scholar
• Han B, Hasin Y. Cardiovascular effects of natriuretic peptides and their interrelation with endothelin-1. Cardiovasc Drugs Ther 2003;17(1):41-52
   Google Scholar
• Sharp A, Mayet J. The utility of BNP in clinical practice. J Renin Angiotensin Aldosterone Syst 2004;5:53
   Google Scholar
• Dawson A, Struthers AD. Vasopeptidase inhibitors in heart failure. J Renin Angiotensin Aldosterone Syst 2002;3(3):156-9
   Google Scholar
• Tabrizchi R. Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. Drugs 2003;63(20):2185-202
   Google Scholar
• Aronson D, Krum H. Novel therapies in acute and chronic heart failure Pharmacology and Therapeutics. 2012;135:1-17
   Google Scholar
• Mcmurray JJ, Packer M, Desai As, et al. Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16(7):817-25
   PubMed Web of Science ®Google Scholar
• Feldman AM, Combes A, Wagner DC, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537
   PubMed Web of Science ®Google Scholar
• Parissis JT, Venetsanou KF, Mentzikof DG, et al. Tumor necrosis factor-alpha serum activity during treatment of acute decompensation of cachectic and non-cachectic patients with advanced congestive heart failure. Cardiovasc J 1999;33:344
   Google Scholar
• Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Kribbs SB, Clubb FJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 1998;97:1382
   PubMed Web of Science ®Google Scholar
• Mann DJ, Mcmurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004;109:76
   Google Scholar
• Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39(1):E1-8
   PubMed Web of Science ®Google Scholar
• Sidik NP, Solomon SD, Latini R, et al. Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT). Cardiovasc Drugs Ther 2011;25(4):315-21
   Web of Science ®Google Scholar
• Gheorghiade M, Böhm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. ASTRONAUT Investigators and Coordinators. JAMA 2013;309(11):1125-35
   PubMed Web of Science ®Google Scholar
• Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the aliskiren trial to minimize outcomes in patients with heart failure (ATMOSPHERE) study. Eur J Heart Fail 2011;13(1):107-14
   PubMed Web of Science ®Google Scholar
• Parving HH, Brenner BM, Mcmurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and studydesign. Nephrol Dial Transplant 2009;24(5):1663-7
   PubMed Web of Science ®Google Scholar
• Mcmurray JJ, Packer M, Desai As, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014;16(7):817-25
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, Mcalister FA. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 2009;30(4):469-77
   PubMed Web of Science ®Google Scholar
• Pitt B, Kober L, Ponikowski P, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 2013;34(31):2453-63
   PubMed Web of Science ®Google Scholar
• Pitt B, Filippatos G, Gheorghiade M, et al. Rationale and design of ARTS :a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 2012;14(6):668-75
   PubMed Web of Science ®Google Scholar
• Greenberg B, Yaroshinsky A, Zsebo Km, et al. JACC Heart Fail 2014;2(1):84-92
   Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39
   PubMed Web of Science ®Google Scholar
• Konoshita T. Do genetic variants of the Renin-Angiotensin system predict blood pressure response to Renin-Angiotensin system-blocking drugs? A systematic review of pharmacogenomics in the Renin-Angiotensin system. CurrHypertens Rep 2011;13(5):356-61
   Google Scholar
• Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med 2008;14(5):510-17
   PubMed Web of Science ®Google Scholar
• Genetically targeted therapy for the prevention of symptomatic atrial fibrillation in patients with heart failure. GENETICAF. Available from: http://clinicaltrials.gov/ct2/show/NCT01970501
   Google Scholar
• A pharmacogenomic study of candesartan in heart failure. J Clin Hypertens (Greenwich) 2011.13(9):639-43. Available from: http://clinicaltrials.gov/ct2/show/NCT00400582)
   Google Scholar